These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 17309421)
1. Nanotherapeutics: new challenges for safety and cost-effectiveness regulation in Australia. Faunce TA Med J Aust; 2007 Feb; 186(4):189-91. PubMed ID: 17309421 [TBL] [Abstract][Full Text] [Related]
2. Toxicological and public good considerations for the regulation of nanomaterial-containing medical products. Faunce TA Expert Opin Drug Saf; 2008 Mar; 7(2):103-6. PubMed ID: 18324873 [TBL] [Abstract][Full Text] [Related]
3. Researching safety and cost-effectiveness in the life cycle of nanomedicine. Faunce T; Shats K J Law Med; 2007 Aug; 15(1):128-35. PubMed ID: 17902495 [TBL] [Abstract][Full Text] [Related]
4. Too small to overlook. Maynard A; Rejeski D Nature; 2009 Jul; 460(7252):174. PubMed ID: 19587746 [No Abstract] [Full Text] [Related]
5. Nanotechnology and nanomaterials: toxicology, risk assessment, and regulations. Fan AM; Alexeeff G J Nanosci Nanotechnol; 2010 Dec; 10(12):8646-57. PubMed ID: 21121378 [TBL] [Abstract][Full Text] [Related]
6. Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal. Faunce TA Aust New Zealand Health Policy; 2007 Jun; 4():9. PubMed ID: 17543114 [TBL] [Abstract][Full Text] [Related]
7. Policy challenges of nanomedicine for Australia's PBS. Faunce TA Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314 [TBL] [Abstract][Full Text] [Related]
8. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315 [TBL] [Abstract][Full Text] [Related]
10. Too small for concern? Public health and nanotechnology. Bowman DM; Fitzharris M Aust N Z J Public Health; 2007 Aug; 31(4):382-4. PubMed ID: 17725022 [TBL] [Abstract][Full Text] [Related]
11. Assessing the safety and cost-effectiveness of early nanodrugs. Vines T; Faunce T J Law Med; 2009 May; 16(5):822-45. PubMed ID: 19554862 [TBL] [Abstract][Full Text] [Related]
12. Nanotherapeutics--product development along the "nanomaterial" discussion. Wacker MG J Pharm Sci; 2014 Mar; 103(3):777-84. PubMed ID: 24481705 [TBL] [Abstract][Full Text] [Related]
13. Maximizing safe design of engineered nanomaterials: the NIH and NIEHS research perspective. Tinkle SS Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):88-98. PubMed ID: 20049833 [TBL] [Abstract][Full Text] [Related]
14. Issues and concerns in nanotech product development and its commercialization. Kaur IP; Kakkar V; Deol PK; Yadav M; Singh M; Sharma I J Control Release; 2014 Nov; 193():51-62. PubMed ID: 24933600 [TBL] [Abstract][Full Text] [Related]
15. A global view of regulations affecting nanomaterials. Hansen SF Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):441-9. PubMed ID: 20533518 [TBL] [Abstract][Full Text] [Related]
17. Nanotechnology in healthcare: are existing laws adequate? Munir AB; Yasin SH Eur J Health Law; 2007 Nov; 14(3):261-72. PubMed ID: 18229763 [No Abstract] [Full Text] [Related]
18. The US must help set international standards for nanotechnology. Murashov V; Howard J Nat Nanotechnol; 2008 Nov; 3(11):635-6. PubMed ID: 18989319 [No Abstract] [Full Text] [Related]